23andMe's struggles are a sign that direct-to-consumer DNA testing needs stronger oversight
23andMe, a major company providing direct-to-consumer genetic testing, has been struggling financially since late 2023. In September 2024, the company's stock hit a rock-bottom of US$0.30, down 96 percent from its peak share ...
Dec 12, 2024
0
0